Indivior (NASDAQ:INDV) PT Lowered to $16.00

Indivior (NASDAQ:INDV) had its target price reduced by investment analysts at Craig Hallum from $20.00 to $16.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price objective suggests a potential upside of 107.79% from the company’s current price.

Separately, Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price target (down from $22.00) on shares of Indivior in a research note on Friday.

Indivior Stock Down 3.5 %

INDV stock traded down $0.28 during mid-day trading on Friday, hitting $7.70. 723,691 shares of the company were exchanged, compared to its average volume of 398,540. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.68 and a current ratio of 0.85. The firm has a market cap of $1.06 billion, a P/E ratio of -7.28 and a beta of 0.68. The firm’s 50 day simple moving average is $11.11 and its 200 day simple moving average is $14.80. Indivior has a 1-year low of $7.46 and a 1-year high of $23.22.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, July 25th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.40 by $0.04. The firm had revenue of $299.00 million for the quarter, compared to the consensus estimate of $285.90 million. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. On average, sell-side analysts predict that Indivior will post 1.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

Hedge funds and other institutional investors have recently made changes to their positions in the company. M&G Plc bought a new position in shares of Indivior in the first quarter valued at $2,518,000. Janus Henderson Group PLC boosted its position in Indivior by 14.2% during the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company’s stock worth $9,424,000 after purchasing an additional 54,750 shares during the period. Vanguard Group Inc. boosted its position in Indivior by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock worth $90,081,000 after purchasing an additional 52,836 shares during the period. Susquehanna International Group Ltd. bought a new position in Indivior during the second quarter worth $3,224,000. Finally, Quadrature Capital Ltd bought a new position in Indivior during the first quarter worth $1,523,000. 60.33% of the stock is owned by institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.